Status | In progress |
Decision | Selected |
Process | STA 2018 |
ID number | 3773 |
Provisional Schedule
Expected publication | 14 September 2022 |
Project Team
Project lead | Daniel Davies |
Email enquiries
- If you have any queries please email TATeam3@nice.org.uk
External Assessment Group | Peninsula Technology Assessment Group (PenTAG), University of Exeter |
Stakeholders
Companies sponsors | Bayer (finerenone) |
Others | Department of Health and Social Care |
NHS Eastern Cheshire CCG | |
NHS England | |
NHS South West Lincolnshire CCG | |
Welsh Government | |
Patient carer groups | Kidney Care UK |
UK Kidney Association | |
Professional groups | Association of British Clinical Diabetologists |
Primary Care Diabetes Society | |
Royal College of Physicians | |
UK Clinical Pharmacy Association | |
Associated public health groups | None |
Comparator companies | AstraZeneca (dapagliflozin) |
Boehringer Ingelheim (empagliflozin) | |
Merck Sharp & Dohme (ertugliflozin) | |
General commentators | All Wales Therapeutic and Toxicology Centre |
British National Formulary | |
Department of Health, Social Services and Public Safety for Northern Ireland | |
Healthcare Improvement Scotland | |
Medicines and Healthcare products Regulatory Agency | |
Scottish Medicines Consortium | |
Welsh Health Specialised Services Committee | |
Welsh Kidney Patients Association | |
Relevant research groups | None |
Timeline
Key events during the development of the guidance:
Date | Update |
---|---|
12 May 2022 - 06 June 2022 | Draft guidance |
14 April 2022 | Committee meeting: 1 |
28 June 2021 | Invitation to participate |
25 June 2021 | In progress. In progress |
03 March 2021 - 31 March 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual